Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.
Last updated: 2026-04-08 15:55:48 ET
CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.
The Highway Trust Fund is projected to reach insolvency in 2028, facing a potential 46% spending cut.
NASA astronaut Victor Glover is earning widespread praise from conservatives after rejecting identity politics in favor of what he described as a shar...
There are billion-dollar rockets, decades of engineering, and the full weight of American ambition behind Artemis II — and then there’s the toilet...
A 59-year-old man lost 25 pounds on Foundayo, the new GLP-1 weight-loss pill
For the past two years, enterprises evaluating open-weight models have faced an awkward trade-off. Google's Gemma line consistently delivered strong p...
Every enterprise running AI coding agents has just lost a layer of defense. On March 31, Anthropic accidentally shipped a 59.8 MB source map file insi...
Called Foundayo, the tablet becomes the second one to receive FDA’s green light after Novo Nordisk’s WegovyThe US Food and Drug Administration (FD...
Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE